Abstract:High affinity binding of peptides to Src homology 2 (SH2) domains, often requires the presence of phosphotyrosyl (pTyr) or pTyr-mimicking moieties in the N-terminal position of the binding ligand. Several reports have shown that Nα-acylation of the critical pTyr residue can result in increased SH2 domain binding potency. For Grb2 SH2 domains which recognize pTyr-Xxx-Asn-NH2 motifs, significant potency enhancement can be incurred by Nα-(3-amino)Z derivatization of tripeptides such as pTyr-Ile-Asn-NH2. Using ligands based on the high affinity pY-Ac6c-Asn-(naphthylpropylamide) motif, (where Ac6c=1-aminocyclohexanecarboxylic acid), additional reports have shown moderate potentiating effects of Nα-oxalyl derivatization. The current study examined variations of the Nα-oxalyl theme in the context of a Xxx-Ac6c-Asn-(naphthylpropylamide) platform, where Xxx=the hydrolytically stable pTyr mimetics phosphonomethyl phenylalanine (Pmp) or carboxymethyl phenylalanine (Cmf). The effects of Nα-(3-amino)Z derivatization were also investigated for this platform, to ascertain whether the large binding enhancement reported for tripeptides such as pTyr-Ile-Asn-NH2 could be observed. In ELISA-based extracellular Grb2 SH2 domain binding assays, it was found for the Pmp-based series, that extending the oxalyl carboxyl out by one methylene unit or replacing carboxyl functionality with a tetrazole isostere, resulted in binding potency greater than the parent Nα-acetyl-containing compound, with enhancement approximating that observed for the Nα-oxalyl derivative. When Cmf was used as the pTyr mimetic, only modest differences in IC50 values were observed for the series. Examination of the Nα-(3-amino)Z derivatized Pmp-Ac6c-Asn-(naphthylpropylamide), showed that binding affinity was reduced relative to the parent Nα-acetyl analogue, in contrast to the reported significant enhancement of affinity observed with other peptide ligands. Treatment of MDA-453 tumor cells, which are mitogenically driven through erbB-2 tyrosine kinase-dependent pathways, with Pmp-containing inhibitors resulted in growth inhibition, with the Nα-oxalyl and Nα-malonyl-containing compounds exhibiting IC50 values (4.3 and 4.6 μM, respectively) approximately five-fold lower than the parent Nα-acetyl-containing compound. Tetrazole and Nα-(3-amino)Z-containing inhibitors were from two- to four-fold less potent than these latter analogues in the growth inhibition assays.

Synthesis and Utilization of Chiral α-Methylated α-Amino Acids with a Carboxyalkyl Side Chain in the Design of Novel Grb2-SH2 Peptide Inhibitors Free of Phosphotyrosine

N-Terminal carboxyl and tetrazole-containing amides as adjuvants to Grb2 SH2 domain ligand binding

Structure-Based Design Of Tripeptide Derivatives Of α-Aminoalkylphosphonate Esters For Prostate-Specific Antigen Inhibition

Design, Synthesis and Biological Evaluation of Novel Tripeptidyl Epoxyketone Derivatives Constructed from Β-Amino Acid As Proteasome Inhibitors.

Molecular Modeling and Molecular Dynamics Simulation Studies on Pyrrolopyrimidine-Based Α-Helix Mimetic As Dual Inhibitors of MDM2 and MDMX

Design, Synthesis, and Biological Evaluation of Novel Phenol Ether Derivatives As Non-Covalent Proteasome Inhibitors.

Exploration on natural product anibamine side chain modification toward development of novel CCR5 antagonists and potential anti-prostate cancer agents

Synthesis and biological evaluation of 2,5-diaryl-1,3,4-oxadiazole derivatives as novel Src homology 2 domain-containing protein tyrosine phosphatase 2 (SHP2) inhibitors

Abstract 2831: Development of Selective GRP94 Inhibitors for the Treatment of Cancer

Structure-based design, synthesis and biological evaluation of aminopyrazines as highly potent, selective, and cellularly active allosteric SHP2 inhibitors

Synthesis and SAR Study of Novel Peptide Aldehydes As Inhibitors of 20S Proteasome

Design and synthesis of improved active-site SHP2 inhibitors with anti-breast cancer cell effects

Design, synthesis, and biological evaluation of Pyrido[1,2-a]pyrimidin-4-one derivatives as novel allosteric SHP2 inhibitors

Design, Synthesis, Antitumor Activity Evaluation, and Molecular Dynamics Simulation of Some 2-Aminopyrazine Derivatives

Design, synthesis, biological evaluation, common feature pharmacophore model and molecular dynamics simulation studies of ethyl 4-(phenoxymethyl)-2-phenylthiazole-5-carboxylate as Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) inhibitors

Design, Synthesis and Evaluation of Thioacetamide‐Tethered Thiadiazole‐1,2,4‐Triazole Hybrids as SHP2 Inhibitors for Cancer Therapy

De novo design of ErbB2 epitope targeting fusion protein stabilized by coiled coil structure.

Synthesis And Biological Evaluation Of Rgd-Conjugated Mek1/2 Kinase Inhibitors For Integrin-Targeted Cancer Therapy

Structural Requirements for Tyr in the Consensus Sequence Y-E-N of a Novel Nonphosphorylated Inhibitor to the Grb2-SH2 Domain.

Design, synthesis and evaluation of acridine derivatives as multi-target Src and MEK kinase inhibitors for anti-tumor treatment.

Integrating amino acids into Bcr-Abl inhibitors: design, synthesis, biological evaluation, and in silico studies